A history of drug-induced immune-mediated thrombocytopenia from exenatide products
And I think the contributions you've made are just so extraordinary
Twice daily n-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial
This position paper expired on Dec 31, 2019
These could include an individuals genetics, current health status, GLP-1 dose, and other medications they take
Critical Trials May Never Take Place Gargs experience offers valuable insights into the risks and benefits of GLP-1s for people with type 1 diabetes, but to really understand the impact of these drugs, there is a need for massive, long, and rigorous randomized controlled trials